Letters FDA on PROMs

Two important points

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5454 (Published 05 October 2010) Cite this as: BMJ 2010;341:c5454
  1. D Rowen, research fellow ,
  2. J Carlton, research associate,
  3. J E Brazier, professor of health economics,
  4. B Mulhern, research associate,
  5. S Palfreyman, research nurse/honorary lecturer,
  6. K Stevens, research fellow,
  7. A Tsuchiya, reader in economics and health economics
  1. 1Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield S1 4DA, UK
  1. d.rowen{at}sheffield.ac.uk

The new Food and Drug Administration (FDA) guidance on patient reported outcome measures (PROMs)1 2 will affect the use of PROMs in clinical trials and thus the evidence available to licensing and reimbursement authorities worldwide.

We have two comments. Firstly, the guidance …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe